Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant CB 2679d/ISU304: Pharmacokinetics, Activity and Safety

Chur Woo You MD PhD, Howard Levy MBBCh PhD, Ho-Jin Shin MD, Jin Kim MD, Jung Han MD, Soo-Jeung Kim MD, Martin Lee PhD, June Young Park PhD, Seung-Beom Hong PhD, and Jamie Ellen Siegel MD

EAHAD
Madrid, Spain
9 February 2018
Disclosure for Howard Levy

In compliance with COI policy, EAHAD requires the following disclosures to the session audience:

<table>
<thead>
<tr>
<th>Shareholder/Role</th>
<th>Catalyst Biosciences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shareholder</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
<tr>
<td>Grant / Research Support</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
<tr>
<td>Consultant</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
<tr>
<td>Employee</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
<tr>
<td>Paid Instructor</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
<tr>
<td>Speaker bureau</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
<tr>
<td>Other</td>
<td>No relevant conflicts of interest to declare</td>
</tr>
</tbody>
</table>

Presentation includes discussion of the following off-label use of a drug or medical device: N/A
CB 2679d/ISU304

- Designed as a best-in-class high potency recombinant Factor IX product
- 22-fold potency advantage over wt-FIX allows subcutaneous administration
- IV half-life 27.0 hours is significantly longer than 21.0 hours for BeneFIX® (p=0.0014)
- SQ delivery significantly increases half-life
- Orphan drug designations have been granted in the US and EU
Phase 1/2 Multi-Dose Study

- N = 11
- Ascending Dose Cohorts followed by Multi-dose SQ Cohort

Previously reported results

- Cohort 1: 22-fold greater potency vs BeneFIX®; Half-life 27.0 vs 21.0 hours
- Cohorts 2 & 3: Bioavailability 18.5%; Half-life 98.7 h similar to IV agents dosed biweekly or weekly
- Cohort 4 dropped as not needed
Cohort 5 FIX Activity Results (140 IU/kg daily SQ) 
Six Days of Dosing With Five Days Follow-up (n=5)

- Median 15.7% FIX activity levels [IQR 14.9-16.6%] reached after 6 daily doses
- Median half-life is 63.2 hours [IQR 60.2-64.0]
- FIX factor levels above (≥12%) are required to eliminate spontaneous hemarthrosis
- Results suggest that long-term dosing of CB 2679d/ISU304 has the potential to maintain FIX activity in the high-mild hemophilia to normal range
Phase 1/2 (ISU-304-001) Safety

- **Cohort 5**
  - Mild injection site adverse events that resolved without sequelae were reported
    - Pain
    - Erythema
    - Redness
  - One subject reported these AEs as moderately severe for the first and second injection and mild for subsequent injections
  - Injection site bruising was seen with initial SQ injections in 2 subjects and did not occur with subsequent injections when FIX activity levels increased to mild hemophilia range
- **Entire study:**
  - No inhibitory antibodies to CB 2679d/ISU304 or FIX were induced to date
CB 2679d/ISU304 Program Conclusions

• CB 2679d/ISU304 was designed as a best-in-class high potency recombinant Factor IX
• 22-fold potency advantage allows subcutaneous administration
• SQ delivery significantly increases half-life to 63.2 hours
• Daily SQ dosing of 140 IU/kg for 6 days resulted in median 15.7% FIX activity
• At the observed rate of increase, higher levels may potentially be achieved over time
  – Collagen saturation may increase bioavailability and result in shortening of the time required to reach target activity levels
  – Lower dose or decreased frequency may be required once target activity level achieved
• SQ dosing may provide superior prophylaxis to IV extended half-life agents
• Phase 2b study will explore:
  – Reduced frequency of dosing
  – IV loading dose to increase collagen IV saturation more rapidly and increase bioavailability
Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant CB2679d/ISU304: Pharmacokinetics, Activity and Safety

Chur Woo You MD PhD, Howard Levy MBCh PhD, Ho-Jin Shin MD, Jin Kim MD, Jung Han MD, Soo-Jeung Kim MD, Martin Lee PhD, June Young Park PhD, Seung-Beom Hong PhD, and Jamie Ellen Siegel MD

EAHAD
Madrid, Spain
9 February 2018